After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
European legislators have reached a deal on a major rewrite of the region's pharma policies, pushing forward a framework ...
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...
About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...
Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...
The new Lilly facilities—which include a $5 billion API plant near Richmond, Virginia, which was announced in September—are ...
The inaugural approval under the program has gone to USAntibiotics and its domestically manufactured extended-release ...
Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26
While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback